In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

"For outpatients with risk factors, as well as their household contacts, antiviral therapy is recommended on the basis that it might help," they wrote. "For outpatients without risk factors, antiviral ...

San Francisco confirmed that a child in the city became the first case of H5N1. A panel of biotech leaders discussed what ...

Between the 2017-2018 and 2023-2024 influenza seasons, the use of antiviral therapy in pediatric patients with influenza declined in both inpatient and outpatient settings.

Having peers facilitate virtual visits may lead to many more patients with hepatitis C receiving treatment and clearing the ...

The global health landscape is constantly challenged by the emergence and re-emergence of viral pathogens. While significant ...

A systematic review and meta-analysis led by Shandong University in China has evaluated the comparative efficacy and safety ...

NanoViricides, Inc. (NYSE American: NNVC) announced it has engaged a Clinical Research Organization (“CRO”) to conduct a Phase II clinical trial for ...

SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has ...

Emerging data suggest that antiviral therapy in the third trimester can prevent immunoprophylaxis failure. To minimize fetal exposure to antiviral agents, antiviral therapy during pregnancy should ...

TEPOXX is the first antiviral therapy for orthopoxviruses approved by Japan's drug regulator in collaboration with the Ministry of Health, Labour, and Welfare. In partnership with Japan Biotechno ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.